CG Oncology (NASDAQ:CGON) Posts Earnings Results, Misses Expectations By $0.24 EPS

CG Oncology (NASDAQ:CGON) posted its earnings results on Friday. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24), FiscalAI reports. The firm had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $0.36 million. CG Oncology had a negative return on equity of 26.58% and a negative net margin of 3,602.68%.

CG Oncology Price Performance

Shares of CG Oncology stock traded up $0.25 on Friday, reaching $75.10. The company had a trading volume of 610,786 shares, compared to its average volume of 925,978. The firm has a market cap of $6.62 billion, a price-to-earnings ratio of -27.92 and a beta of 0.23. The firm’s 50-day moving average price is $67.12 and its two-hundred day moving average price is $63.95. CG Oncology has a 1 year low of $23.65 and a 1 year high of $77.00.

CG Oncology News Summary

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $82 to $85 and assigned an “overweight” rating, implying approximately 13.2% upside. Benzinga
• Positive Sentiment: Truist Financial also raised its target from $82 to $85 and upgraded its view to “buy,” citing a more constructive outlook for CG Oncology. The Fly
• Positive Sentiment: HC Wainwright maintained a “buy” rating and a $100 target. The firm modestly increased its long-term FY2030 EPS forecast to $6.88 from $6.77, reinforcing expectations for significant future earnings growth as the company advances its pipeline. MarketBeat
• Positive Sentiment: CG Oncology reported second-quarter revenue of $1.16 million, substantially above the $0.36 million consensus estimate, while also highlighting pipeline and business progress. CG Oncology Second-Quarter Results
• Neutral Sentiment: Royal Bank of Canada lowered its target from $81 to $79 but retained an “outperform” rating. The reduced target still represents roughly 5.2% potential upside and may reflect valuation calibration rather than a fundamental downgrade. Ticker Report
• Negative Sentiment: CG Oncology reported a quarterly loss of $0.90 per share, wider than the $0.66 consensus loss and the $0.54 loss recorded a year earlier. The earnings shortfall could limit gains despite strong analyst targets. Zacks Q2 Earnings Report
• Negative Sentiment: HC Wainwright reduced its FY2029 EPS estimate from $2.43 to $2.34, signaling some moderation in its intermediate-term earnings outlook, although its buy rating and $100 target remain unchanged.

Analysts Set New Price Targets

A number of research firms have recently commented on CGON. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of CG Oncology in a research report on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research note on Friday, July 17th. Royal Bank Of Canada lowered their price objective on shares of CG Oncology from $81.00 to $79.00 and set an “outperform” rating for the company in a research report on Friday. Wedbush lifted their price objective on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $83.18.

Insider Activity at CG Oncology

In other CG Oncology news, Director James Mulay sold 24,165 shares of CG Oncology stock in a transaction on Friday, July 10th. The shares were sold at an average price of $75.16, for a total transaction of $1,816,241.40. Following the completion of the transaction, the director directly owned 24,165 shares of the company’s stock, valued at $1,816,241.40. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Leonard E. Post sold 5,000 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $70.00, for a total transaction of $350,000.00. Following the transaction, the director owned 5,000 shares in the company, valued at $350,000. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 37,129 shares of company stock worth $2,663,817. Company insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On CG Oncology

A number of large investors have recently made changes to their positions in the company. Wellington Management Group LLP raised its position in CG Oncology by 8.8% in the 4th quarter. Wellington Management Group LLP now owns 5,999,790 shares of the company’s stock worth $249,111,000 after purchasing an additional 487,011 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of CG Oncology by 116.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company’s stock valued at $142,961,000 after buying an additional 1,854,386 shares during the period. State Street Corp grew its stake in shares of CG Oncology by 46.4% during the fourth quarter. State Street Corp now owns 2,996,695 shares of the company’s stock valued at $124,423,000 after buying an additional 950,028 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of CG Oncology by 15.0% during the second quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company’s stock valued at $56,270,000 after buying an additional 281,637 shares during the last quarter. Finally, RTW Investments LP raised its holdings in shares of CG Oncology by 18.3% in the fourth quarter. RTW Investments LP now owns 2,012,127 shares of the company’s stock worth $83,544,000 after buying an additional 310,911 shares during the period. 26.56% of the stock is owned by hedge funds and other institutional investors.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.